Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | ESRRA | P11474 | 1/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 18/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2696392 | 0.91 | ESRRA (0.66) | ARESRRASLC22A12CYP2C9CYP2C19 | |
| SCHEMBL14663584 | 0.90 | PLA2G7 (0.47) | ARESRRASLC22A12 | |
| SCHEMBL14656131 | 0.89 | SLC22A12 (0.51) | ARESRRASLC22A12CYP3A4CYP2C8 | |
| SCHEMBL14662245 | 0.89 | AR (0.50) | ARESRRASLC22A12CYP3A4CYP2C8 | |
| SCHEMBL3696845 | 0.87 | AR (0.51) | ARESRRASLC22A12 | |
| SCHEMBL9889474 | 0.87 | PLA2G7 (0.51) | ARESRRASLC22A12KCNH2 | |
| SCHEMBL14656186 | 0.87 | SLC22A12 (0.51) | ARESRRASLC22A12CYP3A4CYP2C8 | |
| SCHEMBL876294 | 0.86 | AR (0.53) | ARESRRA | |
| SCHEMBL875311 | 0.83 | PLA2G7 (0.58) | ARESRRA | |
| SCHEMBL14656239 | 0.83 | SLC22A12 (0.47) | ARESRRASLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346549-A2 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250084023-A2 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2025-03-13 | — | — | US | disclosed |
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| US-20240140895-A1 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2024-05-02 | — | — | US | disclosed |
| US-20200055863-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-20200055863-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-10428078-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-10428078-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3172211-B1 | TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2739627-A1 | 2,3-DIHYDROIMIDAZO[1,2-C]PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA² INHIBITORS | Glaxo Group Limited (GB) | 2014-06-11 | — | — | EP | disclosed |
| EP-2736908-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | Glaxo Group Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055863-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | AR 4494/4885ESRRA 4402/4885SLC22A12 3059/4885 |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | PLA2G7, PLA2G4A, PLA2G1B | AR 4584/4885ESRRA 4814/4885SLC22A12 3061/4885 |
| US-20250084023-A2 | NOVEL AROMATIC MOLECULES | AHR, TYR, MUSK | AR 64/4885ESRRA 2617/4885SLC22A12 1291/4885 |
| US-10428078-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | AR 4494/4885ESRRA 4402/4885SLC22A12 3059/4885 |
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | AR 4494/4885ESRRA 4402/4885SLC22A12 3059/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | AR 4420/4885ESRRA 4156/4885SLC22A12 3088/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | AR 4494/4885ESRRA 4402/4885SLC22A12 3059/4885 |
| US-20250346549-A2 | NOVEL AROMATIC MOLECULES | AHR, TYR, MUSK | AR 64/4885ESRRA 2617/4885SLC22A12 1291/4885 |
| US-20240140895-A1 | NOVEL AROMATIC MOLECULES | AHR, TYR, MUSK | AR 64/4885ESRRA 2617/4885SLC22A12 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.